Zileuton for Food Allergy
Investigation of Zileuton as a Novel Treatment to Prevent Anaphylaxis for Children and Adolescents With Food Allergies
Our proposed project will seek to determine if an oral medication called zileuton, which blocks the synthesis of inflammatory molecules called leukotrienes that are involved in allergic reactions, may be able to decrease absorption of food allergens and prevent severe food allergy reactions from occurring. Our study will measure levels of peanut in the blood before and after subjects consume an allergen they can tolerate and compare the results with and without administration of the study medication, zileuton. If our study shows that zileuton can decrease the absorption of a food allergen, this will allow us to see if this medication can be used to prevent anaphylaxis to food.
The goal of this proof-of-concept study is to determine whether zileuton inhibits food allergen absorption in children and adolescents with food allergy. The main questions it aims to answer are:
- Does zileuton administration impact food allergen absorption in children and adolescents with food allergies?
- What is the variability of food allergen absorption in children and adolescents with IgE-mediated food allergies?
Researchers will compare levels of peanut allergen proteins in the participants' blood with and without a dose of zileuton prior to a test meal of peanut protein.
- Visit 1 will involve a baseline blood draw, a test meal of peanut protein and a post-meal blood draw.
- Visit 2 will involve a baseline blood draw, a dose of zileuton before the test meal of peanut protein, and blood draws after the test meal.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Abigail Lang, MD, MSCI
- Numéro de téléphone: "0", 76474 800-543-7362
- E-mail: AllergyResearchNurse@luriechildrens.org
Sauvegarde des contacts de l'étude
- Nom: Michelle Catalano, BS, LPN
- Numéro de téléphone: "0", 76455 800-543-7362
- E-mail: MCatalano@luriechildrens.org
Lieux d'étude
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Recrutement
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
Contact:
- Michelle Catalano, BS, LPN
- Numéro de téléphone: "0", 76455 800-543-7362
- E-mail: MCatalano@luriechildrens.org
-
Chercheur principal:
- Abigail Lang, MD, MSCI
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Adolescent subjects ages 12-17
-
Parent or guardian fluent in English
-
Known IgE-mediated food allergy other than peanut
-
Confirmed by clinical history of reaction to the food antigen plus
- positive skin prick testing and/or serum food-specific IgE AND
- confirmation of the food allergy diagnosis by a board-certified allergist
-
Exclusion Criteria:
- A previous positive peanut specific IgE test or skin prick test, or a history of any allergic symptoms following peanut consumption
- Medical conditions known to affect the gastrointestinal tract
- Any history of hepatic disease or previous abnormal liver function tests
- Previous hypersensitivity or anaphylaxis to zileuton
- Current use of a medication known to interact with zileuton, such as theophylline, warfarin, or propranolol
- History of drug or alcohol abuse
- Use of any investigational drugs within 30 days of screening
- Initiation of allergen immunotherapy within 3 months prior to Visit 1 or a plan to begin therapy during the trial
- Use of leukotriene antagonists/modifier such as montelukast
- Pregnant persons
- Individuals with uncontrolled neuropsychiatric disorders
- Use of oral corticosteroids (OCS) within 2 weeks before screening or are scheduled to receive OCS during the study period for another condition
- Monoclonal antibody or immunosuppressive treatment within 3 months of screening
- Past or current medical problems which in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or may compromise the quality of the data obtained from the study
- Inability or unwillingness of a parent or guardian to give written informed consent or participant to give assent
- Non-English speaking participants
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Study treatment
Treatment with a single dose of Zileuton administered at Visit 2. |
Zileuton is available in 600 mg strength yellow-colored oval tablets. A single dose of 1200 mg zileuton ER (two 600 mg zileuton tablets) will be administered to each participant.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Inhibition of food allergy absorption by zileuton
Délai: 1.25 hours pre-meal and 1 hour post-test meal (Visit 1, Baseline); 2.25 hours pre-test meal and 0.25, 0.5, 1 hour post-test meal (Visit 2, 7 days after Visit 1)
|
Comparison of serum peanut antigen levels pre- and post-peanut test meal will be performed in each participant for Visit 1 (baseline) and Visit 2 (with study drug) to determine absorption of peanut. Comparison of post-meal peanut levels with and without zileuton treatment in each participant will also be performed to see whether gut permeability to peanut changes with study drug administration. |
1.25 hours pre-meal and 1 hour post-test meal (Visit 1, Baseline); 2.25 hours pre-test meal and 0.25, 0.5, 1 hour post-test meal (Visit 2, 7 days after Visit 1)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Variability in allergen absorption in children and adolescents with food allergy
Délai: 1.25 hours pre-meal and 1 hour post-test meal (Visit 1, Baseline); 2.25 hours pre-test meal and 0.25, 0.5, 1 hour post-test meal (Visit 2, 7 days after Visit 1)
|
Comparison of peanut antigen levels between participants to assess any variability in absorption of food antigens between individuals. |
1.25 hours pre-meal and 1 hour post-test meal (Visit 1, Baseline); 2.25 hours pre-test meal and 0.25, 0.5, 1 hour post-test meal (Visit 2, 7 days after Visit 1)
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STUDY00001016
- GIF00000023 (Autre subvention/numéro de financement: Cures Within Reach)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .